Fig. 4.
From: Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
18F-FDG PET/CT images of the patient two months after initiation of therapy with Erlotinib. MIP image (3a) shows mild focal FDG uptake in the left axillary region, lower abdominal and pelvic regions, which decreased since the previous PET/CT image (2a). Transaxial CT images (3b, 3d, 3f, 3h) show significant reduction in size of the left axillary lymph node, anterior abdominal wall lesion and omental/mesenteric deposits metastatic lesions (partial response, RECIST criteria) and fused PET/CT images (3c, 3e, 3f, 3i- arrows) show decrease in metabolic activity of the of the corresponding lesions suggestive of partial metabolic response